Art. -Nr.: HY-18976

UF010

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

UF010 is a selective inhibitor of class I HDAC. UF010 has cytotoxicity to cancer cells and reduces neuroinflammation in the hippocampus. UF010 can be used for the research of neurological diseases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 537672-41-6
Formel: C₁₁H₁₅BrN₂O
Molecular Weight:271.15

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

UF010 Chemical Structure

CAS. Nr.: 537672-41-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

HDAC1

1.42 μM ()

HDAC2

0.32 μM (IC₅₀)

HDAC3

256.7 nM (IC₅₀)

HDAC6

18.93 μM (IC₅₀)

HDAC8

3.97 μM (IC₅₀)

IL-6

Alle JAK Isoform-spezifische Produkte anzeigen :

Alle HDAC Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	7.72 μM Compound: UF010	Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37660352]
4T1	IC₅₀	8.4 μM Compound: UF010	Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell viability for 72 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell viability for 72 hrs by MTT assay	[PMID: 35635949]
A549	IC₅₀	20.81 μM Compound: UF010	Cytotoxicity against human A549 cells assessed as inhibition of cell viability for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability for 72 hrs by MTT assay	[PMID: 35635949]
B16-F10	IC₅₀	2.41 μM Compound: UF010	Cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell viability for 72 hrs by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell viability for 72 hrs by MTT assay	[PMID: 35635949]
HEK293	IC₅₀	98.52 μM Compound: UF010	Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability for 72 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability for 72 hrs by MTT assay	[PMID: 35635949]
HEK293	IC₅₀	98.52 μM Compound: UF010	Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37660352]
MCF-10A	IC₅₀	99.3 μM Compound: UF010	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37660352]
MCF7	IC₅₀	15.36 μM Compound: UF010	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37660352]
MCF7	IC₅₀	17.93 μM Compound: UF010	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability for 72 hrs by MTT assay	[PMID: 35635949]
MDA-MB-231	IC₅₀	24.74 μM Compound: UF010	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37660352]
MDA-MB-231	IC₅₀	24.74 μM Compound: UF010	Cytotoxicity against wild type human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against wild type human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37660352]
MDA-MB-453	IC₅₀	25.34 μM Compound: UF010	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37660352]
RAW264.7	IC₅₀	121.1 μM Compound: UF010	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability for 72 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability for 72 hrs by MTT assay	[PMID: 35635949]

In Vitro

UF010 (500 nM, 4 days) leads to a signifcant reduction in rod production with a concomitant increase in Müller cells^[1].
UF010 (10-100 μM, 72 h) has cytotoxicity to B16F10 cells, MCF-7 cells, A549 cells, 4T1 cells, HEK-293 cells and HCEC cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay ^[2]

Cell Line:

B16F10 cells, MCF-7 cells, A549 cells, 4T1 cells, HEK-293 cells and HCEC cells
Concentration:

10 μM, 100 μM
Incubation Time:

72 h
Result:

Showed IC₅₀ values of 2.41 μM for B16F10 cells, 20.81 μM for A549 cells, 17.93 μM for MCF-7 cells, 8.40 μM for 4T1 cells, 98.52 μM for HEK-293 cells, 95.4 μM for HCEC cells.

In Vivo

UF010 (15 mg/kg, Intraperitoneal injection, single dose) contributes considerably to the inflammatory regulation of hippocampal neurons in postoperative cognitive dysfunction (POCD) mice^[4].
UF010 (15 mg/kg, Intraperitoneal injection, single dose) has antitumor therapeutic efficacy in the 4T1-Luc tumor-bearing mouse model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

postoperative cognitive dysfunction (POCD) mice^[4]
Dosage:

15 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Weakened the infiltration of CD4+ T cells and NK cells in hippocampal tissues.
Reduced inflammatory parameters in serum and hippocampal tissues, such as interleukin 6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor alpha (TNF-α) levels.
Activated the NF-κB/p65, JAK/STAT and TLR/MyD88 pathways.

Animal Model:

4T1-Luc tumor-bearing mouse model^[5]
Dosage:

15 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Inhibited the tumor growth rate percentage to 55.56, 38.36, 39.52% at days 7, 14, and 21.
Induced high levels of ROS generation, causing apoptosis-mediated tumor cell death.

Chemical Information

CAS. Nr. 537672-41-6
Appearance Solid
Molecular Weight 271.15
Formel C₁₁H₁₅BrN₂O
Color White to off-white
SMILES

O=C(NNCCCC)C1=CC=C(Br)C=C1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
J Healthc Eng

Astragaloside IV Reduces OxLDL-Induced BNP Overexpression by Regulating HDAC. [Abstract]

2021 Dec 3;2021:3433615. PMID: 34900182

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (368.80 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6880 mL

18.4400 mL

36.8800 mL

5 mM

0.7376 mL

3.6880 mL

7.3760 mL

10 mM

0.3688 mL

1.8440 mL

3.6880 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Mattar P, et al. A Casz1–NuRD complex regulates temporal identity transitions in neural progenitors [J]. Scientific reports, 2021, 11(1): 3858. [Content Brief]

[2]. Pulya S, et al. Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer [J]. European Journal of Medicinal Chemistry, 2022, 238: 114470. [Content Brief]

[3]. Dai Y, et al. Classical HDACs in the regulation of neuroinflammation[J]. Neurochemistry International, 2021, 150: 105182. [Content Brief]

[4]. Yang C X, et al. The inhibitory effects of class I histone deacetylases on hippocampal neuroinflammatory regulation in aging mice with postoperative cognitive dysfunction [J]. European Review for Medical & Pharmacological Sciences, 2020, 24(19). [Content Brief]

[5]. Pulya S, et al. Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer [J]. Journal of Medicinal Chemistry, 2023, 66(17): 12033-12058. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6880 mL	18.4400 mL	36.8800 mL	92.1999 mL
	5 mM	0.7376 mL	3.6880 mL	7.3760 mL	18.4400 mL
	10 mM	0.3688 mL	1.8440 mL	3.6880 mL	9.2200 mL
	15 mM	0.2459 mL	1.2293 mL	2.4587 mL	6.1467 mL
	20 mM	0.1844 mL	0.9220 mL	1.8440 mL	4.6100 mL
	25 mM	0.1475 mL	0.7376 mL	1.4752 mL	3.6880 mL
	30 mM	0.1229 mL	0.6147 mL	1.2293 mL	3.0733 mL
	40 mM	0.0922 mL	0.4610 mL	0.9220 mL	2.3050 mL
	50 mM	0.0738 mL	0.3688 mL	0.7376 mL	1.8440 mL
	60 mM	0.0615 mL	0.3073 mL	0.6147 mL	1.5367 mL
	80 mM	0.0461 mL	0.2305 mL	0.4610 mL	1.1525 mL
	100 mM	0.0369 mL	0.1844 mL	0.3688 mL	0.9220 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

UF010

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Pattern Recognition Receptors Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) UF010

Alle JAK Isoform-spezifische Produkte anzeigen

Alle HDAC Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

UF010 Related Classifications

HY-18976 Related Classifications